MiRXES will use the fresh capital to expedite plans to deliver non-invasive screening tests for early detection of six major cancers, and to expand its RNA technology for cardiovascular, metabolic and infectious diseases research and diagnostics globally.
Singaporean biotechnology startup MiRXES Pte raised US$77 million ($104.1 million) from investors led by CR-CP Life Science Fund to deliver early detection tests for cancer and other diseases.
Other backers in the Series C funding round include Rock Springs Capital, EDBI, CCB International Holdings Ltd. and Keytone Ventures, the company said in a statement. The round, which brings the total amount of money raised to date to US$120 million, values the seven-year-old startup at US$500 million, according to a person with knowledge of the matter who asked not to be identified.
